Drug intelligence / Profile preview

SMP-656

Development stage: Phase 2
Lead developer: Xilinglab
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SMP-656 is a HER2-targeting antibody-drug conjugate (ADC) developed using the XL-XDC platform by Xiling Lab. It utilizes eribulin as its cytotoxic payload, which acts as a tubulin inhibitor, and is linked to the antibody via a proprietary SuperHydro linker designed to enhance stability and payload delivery. The drug aims to overcome resistance seen with other approved ADCs or cytotoxic agents targeting HER2. SMP-656 is currently in Phase 1 clinical trials for advanced solid tumors expressing or mutated HER2.

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on SMP-656.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMP-656.

Explore the full profile